4//SEC Filing
Harper Molly 4
Accession 0001161697-24-000491
CIK 0001369568other
Filed
Nov 28, 7:00 PM ET
Accepted
Nov 29, 8:09 PM ET
Size
8.9 KB
Accession
0001161697-24-000491
Insider Transaction Report
Form 4
Harper Molly
Director
Transactions
- Exercise/Conversion
Common stock, par value $0.001 per share
2024-11-27$5.78/sh+17,500$101,150→ 17,500 total - Sale
Common stock, par value $0.001 per share
2024-11-27$22.00/sh−17,500$385,000→ 0 total - Exercise/Conversion
Options to purchase common stock
2024-11-27−17,500→ 134,020 totalExercise: $5.78Exp: 2028-06-29→ Common Stock (17,500 underlying)
Footnotes (2)
- [F1]Shares were sold on the open market for personal reasons and to fund the exercise price of the stock options, and not as a result of any disagreement with the Company.
- [F2]Options vested in three annual tranches beginning on June 29, 2022.
Documents
Issuer
CATALYST PHARMACEUTICALS, INC.
CIK 0001369568
Entity typeother
Related Parties
1- filerCIK 0001871470
Filing Metadata
- Form type
- 4
- Filed
- Nov 28, 7:00 PM ET
- Accepted
- Nov 29, 8:09 PM ET
- Size
- 8.9 KB